Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alda-341 in Salivary Gland Tumors
NCT04296266Phase 1Completed
- Sponsor
- Stanford University
- Start
- Feb 2016
- Primary completion
- Dec 2017
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of d-limonene in parotid gland tumor and Submandibular gland tumor, sponsored by Stanford University. Primary endpoint: Bioavailability of Alda-341 in salivary gland tissue using GCMS at 2 weeks. Started Feb 2016; status: completed.
02
Drugs
d-limonene
03
Conditions
parotid gland tumorSubmandibular gland tumor
Beyond the preview
Go deeper on NCT04296266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04296266.